- Home
- ABLV vs CRIS Comparison
ABLV vs CRIS Comparison
Compare ABLV & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | CRIS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 14.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ABLV | CRIS |
|---|---|---|
| Price | $0.70 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 1.1M | 119.8K |
| Earning Date | 01-06-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $114,319,869.00 | $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | $15.56 | ★ N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $0.59 | $1.02 |
| 52 Week High | $1.77 | $4.50 |
Technical Indicators
Market Signals| Indicator | ABLV | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 36.38 |
| Support Level | $0.74 | $1.02 |
| Resistance Level | $0.85 | $1.41 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.00 | 10.28 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.